Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03567057 (ClinicalTrials.gov)	July 18, 2018	22/5/2018	A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment	Multiple Sclerosis;Walking Impairment	Drug: ADS-5102, 274 mg	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	424	Phase 3	United States;Canada
2	NCT03436199 (ClinicalTrials.gov)	March 29, 2018	12/2/2018	Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment	A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102, 137 mg;Drug: ADS-5102, 274 mg;Other: Placebo	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	558	Phase 3	United States;Canada
3	NCT02471222 (ClinicalTrials.gov)	May 2015	11/6/2015	Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment	Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102;Other: Placebo	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	60	Phase 2	United States